

# Index

Page numbers followed by italicized *b*, *f*, and *t* indicate boxes, figures, and tables, respectively.

## A

---

### Access

#### barriers to

for elderly, 263, 265

insurance and, 12–13, 268

children and, 253

elderly and, 265

as reason for nonutilization, 84*t*–86*t*

removal of, 4, 12–13, 19, 268, 286

and dental care utilization, among military vs. civilian population, 83, 87, 88*f*

ACF. *See* Administration for Children and Families

### Acids

and caries, 37–38

saliva and, 27

and tooth surfaces, 31

*Actinobacillus actinomycetemcomitans*

and adult periodontitis, 40

and bacteremia, 104

and early-onset periodontitis, 42, 205

and periodontal disease, 203*t*

Administration for Children and Families (ACF), 226, 226*t*

Adolescents/young adults, 257–258. *See also* Children

Adult periodontitis, 40–42

bacterial activity in, 40, 203*t*, 204–205

diagnosis of, 204–205, 204*t*

immune response to, 40–41

progression of, 40

rapidly progressing, 40, 41, 207

refractory, 42

susceptibility factors, 41

systemic antibiotics for, 207

Adult respiratory distress syndrome (ARDS), 105

African Americans. *See also* Race/ethnicity

#### cancer in

incidence of, 68, 68*f*

survival rates for, 68–69, 69*f*

children, insurance coverage of, 253, 278

congenital malformations in, 72, 72*f*

dental care among

nonutilization of, 83, 84*t*

utilization of, 80*t*, 81–82, 81*t*

dental caries in, 63–64, 63*f*, 64*f*

as dental personnel, 236–237, 237*t*

oral and pharyngeal cancers in

diagnosis of, 69, 69*f*

by sex, 68, 68*f*

oral health status of, 74–75

periodontal disease in, 65–66, 66*f*

and ratings of oral health, 144

tobacco use by, 260*b*

tooth loss in, by economic status, 67, 67*f*

toothaches among, prevalence of, 73

### Age

and canker sores, prevalence of, 71, 71*f*

and dental care

nonutilization, 83, 84*t*

utilization, 80–81, 80*t*

and dental caries, by economic status and race/ethnicity, 63–64

and injuries, 72–73

and insurance coverage, 231

and oral-facial pain, prevalence of, 73, 73*f*

oral health data on, 2–3

oral health vulnerabilities according to, 249–267

and oral herpes lesions, prevalence of, 70–71, 71*f*

and periodontal disease, 65–66, 65*f*, 203*t*

adult periodontitis, 41

by race/ethnicity, sex, and economic status, 65–66

- Age (*continued*)  
 and ratings of oral health, 144  
 and tooth loss, 66
- Agency for Healthcare Research and Quality (AHRQ), 171, 172, 213, 225, 226t
- Aging, and craniofacial complex, 31–32
- AHRQ. *See* Agency for Healthcare Research and Quality
- AIDS. *See also* HIV infection  
*Candida* infections with, 43  
 esophageal candidiasis with, 101  
 and oral cancer, 46
- Alcohol, 191t  
 community programs, 171  
 as general health risk factor, 10  
 in mouthwash, and oral cancer, 210  
 and oral cancer, 44–45, 46, 169, 208t, 209, 209t  
 tobacco and, combination of, and oral cancer, 45, 208t, 209
- Allodynia, 52
- Allografts, 208–209
- Alloplasts, 209
- Allopurinol mouthwash, and mucositis, 106
- Alpha tocopherol, 47, 251b
- Alveolar bone. *See also* Jaw; Oral bone  
 aging and, 31–32  
 loss of, 32  
 osteoporosis and, 102–103  
 risk factors for, 203t  
 smoking and, 41  
 nutrition and, 250b  
 regeneration of, 208–209
- Amelogenesis imperfecta, 49, 278
- American Indians/Alaska Natives  
 children of, oral health of, 76–77  
 as dental personnel, 236, 237t  
 oral and pharyngeal cancers and, by sex, 68, 68f  
 oral clefts, 72  
 oral health status of, 76–77  
 Pima tribe, in diabetes-periodontal disease study, 113–114  
 and precancerous lesions from smokeless (spit) tobacco, 70  
 and ratings of oral health, 144
- American Society of Anesthesiologists, classification of patient's risk, 196, 197t
- Americans Stop Smoking Intervention Study for Cancer Prevention (ASSIST), 171
- Anaerobes, gram-negative, 39
- Andersen behavioral model, 248–249, 248f
- Anodontia  
 in ectodermal dysplasias, 50  
 hereditary, 49
- Antibiotics  
 and disruption of oral homeostasis, oral candidiasis and, 42  
 systemic, for periodontitis, 206t, 207
- Antibodies. *See also* IgA antibody; Immunoglobulins  
 in adult periodontitis, 40–41  
 in mucosal immune system, 28  
 oral fluids in diagnostic tests for, 103, 103t
- Anticipatory guidance, for children, 256
- Antigenic components, in identification of periodontopathic bacteria, 205
- Antimicrobial agents, for periodontal diseases, 206t, 207
- Antimicrobial components, in saliva, 27
- Antioxidants, 47
- Apert's syndrome, 49
- Aphthous ulcers, recurrent, lesions caused by, 100t
- Apoptosis  
 and oral cancer, 45, 46  
 Sjögren's syndrome and, 51
- ARDS. *See* Adult respiratory distress syndrome
- Arthritis, jaw manifestations of, 52
- Ascorbate, and gingivitis, 250b
- Asians/Native Hawaiians/Pacific Islanders. *See also* Chinese Americans; Vietnamese Americans  
 as dental personnel, 236, 237t  
 oral and pharyngeal cancers and, by sex, 68, 68f  
 oral health status of, 76
- Aspartate aminotransferase, in adult periodontitis, 205
- Assaults. *See* Violence
- ASSIST. *See* American Stop Smoking Intervention Study for Cancer Prevention
- Association of State and Territorial Dental Directors (ASTDD), 226–227
- ASTDD. *See* Association of State and Territorial Dental Directors
- Autografts, 208
- Autoimmune disorders, 212  
 Sjögren's syndrome, 51

---

**B**

- B cells, 28
- Bacteremia  
 infective endocarditis and, 107–108  
 and microthrombosis, 117–118  
 and oral infection, 104–105
- Bacteria. *See also specific bacteria*  
 in adult periodontitis, 40, 41, 204–205  
 in dental caries, 37–38  
 in early-onset periodontitis, 42, 205  
 in gingivitis, 39  
 gram-negative, and adult periodontitis, 40  
 in heart disease, 117–118

- lesions caused by, 99t  
 in periodontal disease, 202, 203t, 204–205  
 in refractory periodontitis, 42
- Bacteroides forsythus*  
 in adult periodontitis, 40, 205  
 in periodontal disease, 203t
- BANA test, in identification of periodontopathic bacteria, 205
- Behçet's syndrome  
 lesions caused by, 100t  
 and RAU, 44
- Benzpyrene, 45
- Betel nuts, and oral cancer, 45
- Biofilm, 26, 37, 104. *See also* Plaque  
 and gingivitis, 39
- Biomarkers  
 future of, 279  
 for oral cancer, 210
- Biomimetics, 279
- Biopsy  
 for mucosal disease diagnosis, 212  
 for oral cancer diagnosis, 210
- Birth control medication, and gingivitis, 39
- Birth defects, craniofacial, 47–50  
 clinical management of, 210–211  
 cultural reactions to, 141  
 point mutations and, 31  
 prevalence of, 71–72  
 prevention and control of, 172–173, 210–211  
   strategies for, 156t  
 secondary to other developmental disorders, 49
- Bone grafts, 208–209
- Bone loss. *See* Alveolar bone, loss of; Oral bone, loss of
- Boston-type craniosynostosis, 49
- Brain abscesses, oral flora and, 105
- Branchial arch(es), 29  
 altered morphogenesis of, birth defects caused by, 47–48
- Bruxism, 52, 190, 191t
- Burkitt's lymphoma, viral causes of, 45
- 
- C**
- 
- Calcium  
 metabolism of, disturbances in, oral manifestations of, 101  
 and periodontal disease, 203t, 250b–251b
- Calcium channel blockers, and gingivitis, 39, 107
- Calculus  
 and adult periodontitis, 40  
 and gingivitis, 39
- Campylobacter*, and gingivitis, 39
- Canadian Task Force on the Periodic Health Examination, 156–158
- Cancer. *See also specific type*  
 oral and pharyngeal, 44–47, 209  
   health care providers' knowledge about, 179  
   HPV and, 43, 45–46, 208t, 209, 210  
   prevention and management of, 47, 169–172  
     community-based interventions, 170–171  
     early diagnosis in, 171–172  
     nutrition in, 210, 251b  
     provider-based, 210  
     strategies for, 156t  
   public knowledge about, 178–179  
   quality of life with, 136, 142  
   risk factors in, 44–47, 208t, 209–210, 209t  
     nutrition and, 251b  
   statistics on  
     incidence rates, 67, 68, 68f, 74  
     mortality rates, by state, 70, 70t  
     site-specific, 69–70  
     sources for, 62  
     stage of diagnosis of, by race/ethnicity, 69, 69f  
     survival rates, 67–69, 74  
   tobacco and, 259b, 260b  
   therapies. *See also* Chemotherapy; Radiation treatment  
     combined, and oral mucositis, 106–107  
   types of  
     incidence rates for, 68, 68f  
     survival rates for, 69, 69f
- Candida albicans*  
 and oral cancer, 46, 209  
 and oral candidiasis, 42
- Candida* infections, 42–43
- Candidal angular cheilosis, 43
- Candidiasis  
 esophageal, 101  
 lesions caused by, 99t  
 oral, 42–43  
   with HIV, 42, 43, 71, 101  
   prevalence of, 71
- Canker sores, 43–44. *See* Recurrent aphthous ulcers (RAU)  
 prevalence of, 71, 71f
- Capnocytophaga*, and prepubertal periodontitis, 42
- Capnocytophaga ochracea*, and localized juvenile periodontitis, 42
- Capsaicin, 25  
 for oral mucositis pain, 106
- Carbamazepine, and tic douloureux, 52

- Cardiovascular disease, oral infection and, 115–120  
 animal studies, 117–118  
 mechanisms of action in, 115–117  
 population-based studies, 118–120, 119t
- Caries. *See* Dental caries
- Cariou lesions, precavitated, in restored teeth,  
 diagnosis of, 198
- Carotenoids, 47, 251b
- Cavities, 37. *See also* Dental caries
- CDC. *See* Centers for Disease Control and Prevention
- Celiac disease, oral manifestations of, 101
- Cements, glass ionomer, in dental caries treatment, 201
- Center for Policy Alternatives, 268
- Centers for Disease Control and Prevention (CDC), 225, 226t
- Cervical cancer, human papillomavirus (HPV) and, 43, 45
- Cervicofacial actinomycosis, lesions caused by, 99t
- Chediak-Higashi syndrome, and periodontal disease, 41
- Chemotherapeutic agents, in plaque reduction, 199
- Chemotherapy  
 oral candidiasis and, 42  
 oral infections from, 105  
 oral ulcers and oral mucositis from, 26
- Chickenpox, oral lesions with, 98t
- Children  
 anticipatory guidance for, 256  
 craniofacial birth defects in. *See* Birth defects, craniofacial  
 dental caries in, 2, 38, 252  
 by economic status and race/ethnicity, 63–64  
 dental risk and protective factors for, 257t  
 dental sealants for, 167–168, 168t  
 with disabilities, 79, 253  
 enamel fluorosis in, 160  
 fluoride for  
 in dietary supplements, 162–165, 164t  
 in mouthrinses, 165  
 in school water, 162  
 from supplement programs, 164–165  
 future of oral care and, 277–278  
 injuries and, 258t, 722  
 insurance coverage, 231, 253, 277–278  
 Medicaid, 2, 253–255, 268  
 State Children's Health Insurance Program, 13, 233–234, 255, 277  
 malocclusion in, risk and protective factors for, 258t  
 oral health of, 2, 249–253  
 barriers to, 13, 286  
 preventive environment for, 255–257, 256t, 257t, 258t  
 periodontal diseases in, risk and protective factors for, 256t  
 poverty and, 2, 252  
 violence and abuse, 51
- Chinese Americans, nasopharyngeal cancer  
 incidence and mortality, 76
- Chlorhexidine  
 to limit gingival inflammation, 205, 206t  
 to prevent mutans streptococci transmission, 200  
 and remineralization, 199  
 teeth stains from, 107
- Chronic and disabling oral conditions, 51–53, 73
- Cigarettes, and oral and pharyngeal cancer, 259b.  
*See also* Tobacco
- Cigars. *See also* Tobacco  
 and oral and pharyngeal cancer, 259b  
 and oral cancer, 208t, 209  
 trends in smoking, 260b
- Cleft lip/palate, 47–48  
 cost of, 228  
 prevalence of, 72, 72f  
 quality of life with, 141–142  
 in Waardenburg syndrome, 50
- Cleft palate, 47–48
- Clefting abnormalities  
 from altered branchial arch morphogenesis, 47–48  
 incisive foramen and, 30
- Cleidocranial dysplasia, 50
- Cochrane Collaboration, 213, 214t, 246
- Collagenase, in adult periodontitis, 205
- COMMIT. *See* Community Intervention Trial for Smoking Cessation
- Community Health Centers, 227, 237
- Community health programs. *See also* Public health programs  
 for craniofacial birth defects, 172–173  
 for dental caries, 158–168  
 evidence of effectiveness of, 155–158  
 glossary of terms, 157b  
 for injury, 173–176  
 for oral and pharyngeal cancers, 169–172  
 for periodontal diseases, 168–169  
 strategies used, 156t
- Community Intervention Trial for Smoking Cessation (COMMIT), 171
- Corticosteroids, and disruption in oral homeostasis,  
 oral candidiasis and, 42
- Cosmetic dentistry, increased demand for, 137–138
- Coxsackievirus, oral lesions with, 98t
- Cranial bones, birth defects involving, 48–49

- Craniofacial complex  
aging of, 31–32  
contact and communication in, 23–25  
diagram of, 22  
functions of, 1, 17  
oral cavity in, 25–28  
origins and development of, 28–31  
  early development of, 29–30  
  genetic controls in, 30–31  
  nutrition in, 250*b*  
research on, 4, 19  
sensory functions of, 23
- Craniofacial defects. *See* Birth defects, craniofacial
- Craniosynostosis, 49, 278  
and gene mutations, 31
- Crohn's disease, and RAU, 44
- Crouzon's disease, 49, 278
- Cryotherapy, for mucositis, 106
- Cuban Americans, oral health of, 75
- Cyclosporin, and gingivitis, 39, 107
- Cytokines, 28  
and adult periodontitis, 40–41  
and periodontal diseases, 203  
and pregnancy, 120–121
- Cytomegalovirus, and chemotherapy, 106
- D**
- 
- Demineralized bone, freeze-dried, in bone grafts, 208–209
- Dental appliances, 201  
and chewing function, 135–136  
and oral candidiasis, 43, 71
- Dental care. *See also* Oral health care system  
active personnel in, 223–224, 224*t*, 235–236, 235*f*  
composition of, by sex and race/ethnicity, 236–237, 237*t*  
annual expenditures on, 223, 228, 228*t*, 231*f*, 231*t*  
per capita, 228, 229*f*  
vs. total health care expenditures, 227, 227*f*, 228*f*  
costs of  
  indirect, 142–144, 143*t*  
  per capita, 228, 229*f*  
  as reason for nonutilization, 83, 84*t*–86*t*  
  vs. other medical services, 228, 230*t*, 231*f*  
disciplines in, 224  
evidence-based, 213, 246, 277  
expenditures on, 227–228  
  by source  
    1960–1996, 231*f*  
    1998, 228*t*  
  vs. total health care expenditures, 227*f*, 228*t*  
financing and reimbursement for, 228*t*, 229–234, 231*f*, 231*t*, 232*f*  
managed, 231–233, 233*t*, 254  
among military personnel, vs. civilian population, 83, 87, 88*f*  
nonutilization of, reasons for, 83, 84*t*–86*t*  
population-to-dentist ratio, 224, 224*f*  
for underserved populations, 239  
unmet needs in, 83, 87*t*  
  for children, 252–253  
utilization of, 80–81, 190–191  
  by sex, race/ethnicity, income, and insurance, 80*t*, 81–82, 81*t*  
  variation by oral health status, 82, 82*t*
- Dental caries, 37–39  
changing clinical approach to, 196–201  
diagnosis of, 198, 200*t*  
multifactorial model in, 196, 197*f*  
prevention of, 198–200, 200*t*  
risk assessment in, 197, 198*f*, 198*t*, 199*t*, 200*t*  
treatment of, 201  
in children, 2, 38, 252  
  by economic status and race/ethnicity, 63–64  
  risk and protective factors for, 257*t*  
classification of, 201  
nutrition and, 250*b*  
prevalence of  
  by age, economic status, and race/ethnicity, 63–65  
prevention of  
  community approaches to, 158–168  
  dental sealants, 166–168  
  dietary fluoride supplements, 162–165  
  fluoridated drinking water, 160–162  
  fluoride mouthrinses, 159*t*, 165  
  fluoride varnishes, 165–166  
  school water fluoridation, 162  
  fluoride in, 2–3, 10, 18, 27, 38, 155, 158–160  
  health care professionals' knowledge about, 177–178  
  provider-based, 198–201  
  public's knowledge about, 177  
  saliva and, 27, 38  
  strategies for, 156*t*  
  target population for, 159*t*  
  daily hygiene, 39, 189–190  
  progression of, 198  
  rate of, 38–39  
  smokeless (spit) tobacco and, 39, 259*b*

- Dental caries (*continued*)  
 susceptibility to, 39  
 tobacco and, 259*b*  
 vaccine for, 200
- Dental hygienists, 235  
 knowledge of dental caries prevention, 177–178  
 knowledge of periodontal disease prevention, 178
- Dental implants, 201
- Dental plans. *See* Insurance
- Dental plaque. *See* Plaque; Biofilm
- Dental practice, 223–224
- Dental schools  
 curriculum needs of, 237–238  
 enrollment, 235  
 of minorities, 236  
 faculty vacancies, 237  
 graduate indebtedness, 237–238
- Dental sealants, 38, 166–168  
 for children, 167–168, 168*t*  
 combined with fluoride use, 167  
 cost-effectiveness of, 168  
 in dental caries treatment, 201  
 effectiveness of, 159*t*, 166–167  
 prevalence of use, by race/ethnicity, 82
- Dentifrice, 159*t*, 176, 177, 179, 189–190
- Dentinogenesis imperfecta, 49
- Dentists  
 availability of, 224  
 charitable care by, 239  
 compensation of  
 from elderly in long-term care, 265  
 from Medicaid, 254  
 increased importance of, 191–192  
 knowledge of dental caries prevention, 177–178  
 knowledge of periodontal disease prevention, 178  
 numbers of, 223–224, 224*t*, 235–236, 235*f*  
 visits to. *See also* Dental care, utilization of  
 and susceptibility to adult periodontitis, 41
- Denture sore mouth, 43
- Denture stomatitis, 43, 71
- Depression  
 atypical facial pain with, 52  
 with cancer, 142  
 with TMD, 140
- Dermatologic diseases, lesions caused by, 100*t*
- Developmental disorders, 47–50  
 clinical management of, 210–211  
 cultural reactions to, 141  
 prevalence of, 71–72  
 prevention and control of, 172–173  
 strategies for, 156*t*
- dfs, definition of, 62*b*
- dft, definition of, 62*b*
- Diabetes mellitus  
 and adult periodontitis, 41  
 and periodontal disease, 2, 17, 109–115  
 research used in, 110*t*, 111*t*–113*t*  
 treatment of, 206  
 type 1, and periodontal disease, 41, 110–113, 114, 203*t*  
 type 2, and periodontal disease, 113–114, 203*t*
- Diagnostic codes, dentistry, 216
- Diagnostics, saliva and oral fluids in, 103–104, 103*t*, 279, 280*t*
- Diet. *See also* Nutrition  
 effect on oral health, 191*t*  
 and oral and pharyngeal cancer, 209*t*  
 poor, as general health risk factor, 4, 10, 18
- DiGeorge syndrome, 48
- Digital radiography, 196
- Dilantin, and gingivitis, 39
- Disability days, due to dental conditions, vs. other conditions, 143, 143*t*
- Disabled population, oral health of, 78–79
- DMFS, definition of, 62*b*
- DMFT, definition of, 62*b*
- DNA  
 in identification of periodontopathic bacteria, 205  
 saliva as source for, 103–104, 103*t*
- Down syndrome, and periodontal disease, 41
- Drug abuse, oral fluids for diagnosis of, 103, 103*t*
- Dry mouth. *See* Xerostomia  
 and dental caries, 38  
 and chewing function, 136  
 and Sjögren's syndrome, 51, 136
- Dysplasia, 46
- 
- E**
- Early and Periodic Screening, Diagnostic and Treatment Service (EPSDT), 254
- Early childhood dental caries (ECC), 38, 228
- Early-onset periodontitis, 42  
 bacteria linked to, 205  
 by sex and race/ethnicity, 66  
 systemic antibiotics for, 207
- Eating problems, and quality of life, 135–136, 136*t*
- ECC. *See* Early childhood dental caries
- Ectodermal dysplasias (EDs), 49–50, 211
- Edentulism  
 by age, economic status, sex and race/ethnicity, 66–67  
 by economic status, 82  
 and heart disease, 119  
 by state, 67*t*

- and stroke, 120
- EDS. *See* Ectodermal dysplasias
- Education level
- and dental care wants, 87*t*
  - and dental visits, 80*t*, 81, 81*t*
  - and insurance coverage, 231, 232*f*
  - and knowledge of periodontal disease, 178
  - and susceptibility to adult periodontitis, 41
- Educational debt, 237–238
- Efficacy, of health programs, vs. effectiveness, 155–156
- EGF. *See* Epidermal growth factor
- Egg polarity genes, 30
- Eikenella corrodens*
- and adult periodontitis, 41
  - and prepubertal periodontitis, 42
- Elastase, in adult periodontitis, 205
- Elderly adults. *See also* Age
- chronic health problems of, 266, 266*t*
  - eating problems of, 135–136, 136*t*
  - oral health of, 3, 262–266, 263*t*, 264*t*.
  - trends in, 265–266
  - research on, 262, 263*t*, 264*t*
  - sleep problems of, 137
  - social functioning of, 138–139, 139*t*
  - women, 266–267
- Electrical resistance measurement, 196
- Enamel
- age and, 31
  - demineralization of, 38, 199
  - remineralization of, 199
  - fluoride and, 159
  - saliva and, 27, 31, 38
- Enamel fluorosis, 160
- Enamel hypoplasia, 101
- from tetracycline, 107
- Endocarditis, infective, oral infection and, 107–108
- Endocrine system
- and disruption in oral homeostasis, oral candidiasis and, 42
  - and immune system, 28
  - nicotine and, and oral and pharyngeal cancers, 46–47
- Environment
- importance of, 248–249, 248*f*
  - improvement of, 268
  - for children, 255–257, 268
- Epidemiologic data, need for. *See* Data
- Epidemiology, definition of, 62*b*
- Epidermal growth factor (EGF), 27
- and oral and pharyngeal cancers, 46
- Epidermolysis bullosa-recessive dystrophic type, 49
- Epithelial cells, cancers of. *See* Squamous cell carcinomas, oral
- Epithelium, 25–26
- aging and, 32
  - nutrition and, 250*b*
- EPSDT. *See* Early and Periodic Screening, Diagnostic and Treatment Service
- Epstein-Barr virus
- and chemotherapy, 106
  - and oral cancer, 45
  - and oral lesions, 98*t*
- Erythema multiforme, lesions caused by, 100*t*
- Erythroplakia lesions, 209
- and squamous cell carcinoma, 44
- Estrogen replacement therapy, and adult periodontitis, 41
- Ethnicity. *See* Race/ethnicity
- Evidence-based practice, 213, 246, 277
- Explorer, visual examination with, for dental caries diagnosis, 198, 200*t*
- 
- F**
- 
- Face. *See also* Craniofacial complex
- appearance of, social responses to, 140–141
  - embryonic formation of, 29
  - as reflection of general health, 97–104
- Falls, 50, 72–73. *See also* Injury
- FDA. *See* Food and Drug Administration
- Federal oral health infrastructure, 226–227, 226*t*
- Federal support
- for dental school programs, 235–236
  - for educational debt, 237
- Fibromyalgia, jaw manifestations of, 52
- Fillings. *See also* Restorations
- materials used in, 201
- Flossing, 39, 176, 190
- and bacteremia, 104
  - and dental caries prevention, 178
  - dental professionals' knowledge of, for dental caries prevention, 178
  - public knowledge of
    - for dental caries prevention, 177
    - and gum disease, 178  - by tobacco users vs. nonusers, 178
- Fluoride, 155, 158–160
- dental professionals' knowledge about, 177
  - in dentifrices, 159*t*, 176, 177, 179, 189–190
  - in dietary supplements, 162–165
  - dosage of, 163, 164*t*
  - effectiveness of, 159*t*, 163–164
  - public knowledge of, 177
  - in drinking water, 2–3, 18, 159*t*, 160–162
  - access to, 161, 162*f*, 162*t*, 163*t*
  - costs of, 161
  - effectiveness of, 159*t*, 160–161

- Fluoride (*continued*)  
 history of, 159  
 public knowledge of, 177  
 recommended concentration levels, 160  
 in schools, 159t, 162  
 enamel hypoplasia from high levels of, 101  
 in mouthrinses, 159t, 165  
 professionally applied, 159–160, 198–199  
 public knowledge about, 177  
 and rate of dental caries progression, 38–39  
 safety of, 160  
 in saliva, dental caries protection from, 27, 38, 159  
 in varnishes, 159t, 165–166
- Folate, and gingivitis, 250b
- Folic acid  
 birth defects and, 47–48, 172  
 cancer and, 251b
- Food and Drug Administration (FDA), 225, 226t
- Fungal diseases, lesions caused by, 99t
- Fusobacterium nucleatum*  
 and gingivitis, 39  
 and smoking, 41
- G**
- 
- Gastroenteritis, oral manifestations of, 101
- Gene therapy, 276
- Genes  
 and periodontal disease, 203, 203t  
 and resistance to dental caries, 39
- Genetic derangements. *See also* Developmental disorders  
 and clefting abnormalities, 48  
 and oral cancer, 46  
 and periodontal disease, 41
- Genetics  
 and control of embryonic development, 30–31  
 and future of oral health, 276, 278–279, 278f  
 and understanding craniofacial development, 28
- Genomic databases, 279
- Geographical region. *See also* Residence, place of  
 and dental care wants, 87t
- Germ cell layers, in craniofacial development, 29
- Gingiva  
 bleeding and inflammation of, as diagnostic test, 204, 204t  
 lesions of, diseases and conditions causing, 98t–99t  
 recession of, age and, 31  
 surface of, 25
- Gingival crevicular fluid, periodontal infection and, 204t, 205
- Gingival erythema, linear, and HIV, 101
- Gingivitis, 39–40  
 with adult periodontitis, 40  
 and heart disease, 119  
 from medication, 107  
 and pregnancy, 122  
 prevention of, 10, 168–169, 190, 191t, 205–206  
 by race/ethnicity, 66
- Global ratings, of oral health, 144
- Glossary, 62b
- $\beta$ -glucuronidase, in adult periodontitis, 205
- Glutathione, 47
- Glycemic control, affected by periodontal disease, 114–115, 116t–117t
- Gonorrhea  
 lesions caused by, 99t  
 pharyngeal, 109
- Growth factors, 27  
 and oral cancer, 46–47  
 in reducing mucositis, 106
- Guided tissue regeneration, 209
- Guidelines, for clinical practice, 213–214, 215t
- Guidelines for School Health Programs to Prevent Tobacco Use and Addiction* (CDC), 170
- Gum disease, prevention of, public knowledge of, 178. *See also* Gingivitis; Periodontal disease
- Gums. *See* Gingiva
- H**
- 
- Hand, foot, and mouth disease, oral lesions with, 98t
- HCFA. *See* Health Care Financing Administration
- Head Start, 226
- Health  
 biopsychosocial model of, 134  
 broadened meaning of, 2, 17–18  
 cultural perspectives on, 134–135  
 determinants of, theories and models of, 246–248, 246f  
 historical trends in  
 life expectancy, 275–276  
 science and technology, 275  
 World Health Organization (WHO) definition of, 133
- Health care  
 evidence-based, 213, 246, 277  
 expenditures on, 227–228  
 Consumer Price Index for, 230t, 231f  
 per capita, 229f  
 by source of funds, 228t  
 by type of service, 227f, 228t, 230t  
 federal and state programs for, 233–234



- oral care in. *See* Dental care; Oral health care system
- personnel in, collaboration with dental care providers, 225, 227
- trends in, 277
- unmet needs in, 83, 87t
- utilization of, 190–191
- Health Care Financing Administration (HCFA), 225
- Health Field Concept, Lalonde's, 247
- Health maintenance organizations (HMOs), 229, 232, 233t
- Health Plan Employer Data and Information Set (HEDIS), 233
- Health professional schools, future of, 276–277. *See also* Dental schools
- Health Professional Shortage Area (HPSA), 227, 237
- Health Resources and Services Administration (HRSA), 225, 226t
- Healthy People 2000, progress in meeting objectives of, 180t
- Healthy People 2010, 4, 19, 247–248, 248f
- objectives of, by age, 268t
- Heart disease. *See* Cardiovascular disease
- HEDIS. *See* Health Plan Employer Data and Information Set
- Herpangina, oral lesions with, 98t
- Herpes labialis lesions
- location, features, and course of, 98t
- prevalence of, by race/ethnicity, 71
- Herpes simplex virus, 43
- and chemotherapy, 106
- lesions from, by population group, 70
- and oral cancer, 45–46, 209, 210
- oral lesions with, 98t
- as pharyngeal infection, 109
- type 1 (HSV-1), 43
- lesions from, 70, 71f
- and oral cancer, 45
- type 2 (HSV-2), 43
- Herpes zoster, oral lesions with, 98t
- Herpetic gingivostomatitis, primary acute, oral lesions with, 98t
- Herpetic stomatitis, primary, 43
- Herpetiform recurrent aphthous ulcers, 44
- HHANES. *See* Hispanic Health and Nutrition Examination Survey
- Hispanic Health and Nutrition Examination Survey (HHANES), 75
- Hispanics. *See also* Cuban Americans; Mexican Americans; Puerto Ricans
- children of
- insurance coverage of, 278
- oral health of, 75
- dental care among
- nonutilization by, 84t–85t
- utilization by, 80t, 81–82, 81t
- as dental personnel, 236–237, 237t
- oral and pharyngeal cancers and, by sex, 68, 68f
- oral health status of, 75–76
- and ratings of oral health, 144
- toothaches among, 73
- Histoplasmosis, lesions caused by, 99t
- HIV/AIDS Dental Reimbursement program, 238–239
- HIV infection
- human papillomavirus (HPV) and, 43, 71
- and oral candidiasis, 42, 43, 71, 101
- oral lesions with, 98t, 101–102
- oral manifestations of, 97, 101–102
- oral transmission of, 108–109
- and periodontal disease, 41
- and RAU, 44
- and trench mouth, 40
- HMOs. *See* Health maintenance organizations
- Hodgkin's lymphoma, 46
- Hom* genes, 30
- Homeotic genes, 30
- Hormones, oral fluids in diagnostic tests for, 103, 103t
- Hospice patients, 263, 266, 266t
- Hospitalized patients, and systemic complications due to oral bacteria, 105
- Hospitals, oral health care at, 225
- Hox* genes, 30
- HPSA. *See* Health Professional Shortage Area
- HPV. *See* Human papillomavirus
- HRSA. *See* Health Resources and Services Administration
- HSV-1. *See* Herpes simplex virus, type 1
- HSV-2. *See* Herpes simplex virus, type 2
- Human genome, in understanding craniofacial development, 28
- Human Genome Project, 53, 278
- Human immunodeficiency virus. *See* HIV infection
- Human papillomavirus (HPV), 43
- and oral cancer, 43, 45–46, 208t, 209, 210
- prevalence of, 71
- Hypodontia
- in ectodermal dysplasias, 50
- hereditary, 49
- Hypoparathyroidism, oral manifestations of, 101

---

**I**

- IFN- $\gamma$ . *See* Interferon  $\gamma$
- IgA antibody, 32

- IHS. *See* Indian Health Service
- IL-1. *See* Interleukin 1
- IL-1 $\beta$ . *See* Interleukin 1 $\beta$
- Imaging technologies, 196  
for dental caries diagnosis and treatment, 201  
for oral cancer diagnosis, 210  
for TMD, 212t
- Immune cells  
in adult periodontitis, 40–41  
and oral cancer, growth factors and, 46–47  
types of, 28. *See also* B cells; T cells
- Immune system, 27–28  
disorders of, Sjögren's syndrome, 51  
and disruption in oral homeostasis, oral  
candidiasis and, 42  
microbial genome research and, 279  
mucosal, 27–28  
nutrition and, 250b  
and RAU, 44
- Immunoglobulins, 28. *See also* IgA antibody  
smoking and, 41
- Immunosuppression  
and bacteremia, 104–105  
oral signs of, 97–100
- Immunosurveillance and control, loss of, and oral  
cancer, 46
- Implants. *See* Dental implants
- Incidence, definition of, 62b
- Incidence rate, definition of, 62b
- Incisive foramen, embryonic formation of, 29–30
- Income  
and adult periodontitis, 41  
and children  
dental caries and, 63–64, 63f, 64f  
and insurance coverage, 253  
oral health and, 2, 252  
dental care and  
nonutilization of, 85t–86t  
utilization of, 80t, 81–82, 81t  
wants, 87t  
and dental caries, 63–64, 63f, 64f  
and edentulism, 82  
and insurance coverage, 231, 232f  
for children, 253  
low-income communities  
dentists in, educational debt and, 237  
expansion of care to, 239  
and oral health, 249  
among Hispanics, 75  
and periodontal disease, 65–66, 66f  
and toothaches, 73
- Indemnity plans, 232, 233t
- Indian Health Service (IHS), 76–77, 225, 226t  
loan repayment program, 237
- Infection, oral. *See also* Mucosal infections;  
Periodontal disease  
bacteremia and, 104–105  
from cancer therapy, 105–107  
infective endocarditis and, 107–108  
protection against. *See also* Immune system  
by mucosal immune system, 27–28  
by saliva, 26–27  
respiratory disease and, 108
- Inflammation, gingival. *See* Gingivitis
- Injury, oral-facial, 50–51. *See also* Falls; Trauma  
in adolescents, 258  
in children, 2, 72, 258t  
prevalence of, 72–73  
prevention and control of, 191t  
community-based, 173–176, 174t–175t  
future of, 276  
helmet use, 173, 174t–175t, 176b  
from sports, 50, 73, 173–176, 174t–175t, 176b,  
258  
in young adults, 258
- Insurance  
changing market in, 231–233  
coverage, 12–13, 229–231  
by age, 231  
for children, 2, 253–255, 277–278  
and dental care nonutilization, 86t  
and dental care utilization, 80t, 81–82, 81t,  
229  
among children, 253  
and dental care wants, 87t  
by education level, 231, 232f  
for elderly, 265  
employer-provided, 229–231, 261–262  
children and, 253  
future goals in, 286  
by income, 231, 232f  
by sex and race/ethnicity, 230–231, 232f
- Medicaid, 87t, 229, 233  
for children, 2, 253–255, 268  
for elderly, 265
- Medicare, 234, 234t, 265  
performance measures in, 232–233  
as source of expenditures on dental services,  
228t, 231f, 231t
- State Children's Health Insurance Program,  
(SCHIP) 2, 13, 233–234, 255, 277  
and utilization, 81t, 82
- Interferon  $\gamma$  (IFN- $\gamma$ ), and adult periodontitis, 41
- Interleukin 1 (IL-1)  
and adult periodontitis, 41, 205  
and periodontal disease, 203

Interleukin 1 $\beta$  (IL-1 $\beta$ )  
 and adult periodontitis, 41  
 and periodontal disease, 203  
 Interleukin 6, and adult periodontitis, 205  
 Interleukins, and heart disease, 115  
 Irrigation, to control gingival inflammation, 206t,  
 207

**J**

---

Jaw (mandible and maxilla). *See also* Alveolar bone;  
 Oral bone  
 aging and, 31–32  
 bone loss in, osteoporosis and, 102–103

**K**

---

Kaposi's sarcoma, 46, 101  
 Keratin, 25  
 Keratin genes, mutations in, and epidermolysis  
 bullosa, 49  
 Keratinocytes, and oral cancer, 46  
 Killer cells, and oral cancer, 46

**L**

---

Lacrimal glands, Sjögren's syndrome and, 51  
 Lalonde Report, 246–247  
 Langerhans cells, and immunosurveillance, 46  
 Language  
 mechanisms of, 25  
 skills, of oral and pharyngeal cancer patients,  
 136  
 Laser technologies, in dental caries diagnosis and  
 treatment, 201  
 Leukoplakias, 44, 209  
 Lichen planus, lesions caused by, 100t  
 Life expectancy, 275–276  
 Lifestyle  
 of adolescents/young adults, 257–258  
 as determinant of health, 190, 191t, 246f,  
 247–248  
 Lip cancer  
 incidence of, 69, 70  
 risk factors, 208t, 209t, 210  
 sun exposure, 169  
 Lips, lesions on, diseases and conditions causing,  
 98t, 100t  
 LJP. *See* Localized juvenile periodontitis  
 Local public health departments, 226, 286  
 Localized juvenile periodontitis (LJP), 42  
 Lymphocytes, and immunosurveillance, 46.  
*See also* B cells; T cells

**M**

---

Macrophages, cytotoxic, and immunosurveillance,  
 46  
 Magnetic resonance imaging (MRI), 196  
 Malocclusions  
 prevalence of, 72  
 quality of life with, 141–142  
 risk and protective factors for, 258t  
 Mandibulofacial dysostosis, 48  
 Marijuana, oral cancer and, 45, 208t, 209t  
 Masseter muscle, 26  
 Mastication, muscles of, 26  
 Mechanoreceptors, 24  
 Medicaid, 229, 233  
 for children, 2, 253–255, 268  
 dental vs. other health expenditures for,  
 254  
 and dental care wants, 87t  
 for elderly, 265  
 Medical care, in oral health care system, 225  
 Medicare, 234, 234t, 265  
 and dental care wants, 87t  
 Medications  
 and dental caries, 38  
 and disruption in oral homeostasis, oral  
 candidiasis and, 42  
 and elderly oral health, 265–266  
 and gingivitis, 39  
 oral complications of, 107  
 Men  
 and adult periodontitis, susceptibility to, 41, 65,  
 65f  
 cancer in  
 oral and pharyngeal, by race/ethnicity and  
 sex, 68, 68f  
 types of, by race/ethnicity, 68, 68f  
 and dental care nonutilization, 84t  
 and injuries, 73  
 and pain, 25  
 prevalence of, 73, 73f  
 and periodontal disease, 203t  
 Metabolites, in detection of periodontal disease, 205  
 Mexican Americans  
 children  
 insurance coverage of, 253  
 oral health of, 75  
 dental care utilization by, 80t, 81–82, 81t  
 and dental caries, susceptibility to, 63–64, 63f,  
 64f  
 tooth loss by, by economic status, 67, 67f  
 Microbes  
 genome research on, 279  
 oral transmission of, 108–109

---

## Index

- Microbes (*continued*)  
  protection against. *See also* Immune system  
    by saliva, 26–27
- Micronutrients. *See also* Nutrition  
  and cancer prevention, 47  
  fluoride as, 160
- Military personnel, dental care among, vs. civilian  
  population, 83, 87, 88*f*
- Mononucleosis, infectious, oral lesions with, 98*t*
- Mortality rate, definition of, 62*b*
- Motor vehicle collisions, 50, 73, 173
- Mouth. *See also* Craniofacial complex; Oral cavity  
  elements of, 1, 17, 25  
  embryonic formation of, 29  
  as gateway, 37  
    for infection, 104–109  
  lesions in, diseases and conditions causing,  
    98*t*–100*t*  
  as reflection of general health, 1–2, 10–11, 17,  
    97–104, 284
- Mouthguard use, 173–175, 174*t*–175*t*, 176*b*
- Mouthrinses, fluoride, 159*t*, 165
- MRI. *See* Magnetic resonance imaging
- Mucins, 27  
  aging and, 32
- Mucosal immune system, 27–28
- Mucosal infections, 42–44, 70–71, 212  
  by race/ethnicity, socioeconomic status, and sex,  
    70–71
- Mucous membrane pemphigoid, lesions caused by,  
  100*t*
- Multiple sclerosis, and tic douloureux, 52
- Mumps, swollen parotid glands with, 97
- Mutans streptococci, 37, 38  
  median age of acquisition of, 39  
  mother as source of, 199–200  
  as primary predictor of dental caries incidence,  
    196–197, 198*t*
- Mutations  
  and craniofacial syndromes, 31, 278–279  
  in keratin genes, and epidermolysis bullosa, 49  
  and oral cancer, 46  
  and periodontal disease, 41
- 
- N**
- Nasopharyngeal carcinoma, 45, 76
- National Facial Protection Month, 173
- National Health and Nutrition Examination Survey  
  (NHANES), 61, 62
- National Health Interview Survey (NHIS), 61
- National Health Service Corps (NHSC), 237
- National Institute for Dental and Craniofacial  
  Research (NIDCR), 213
- National Institutes of Health (NIH), 225, 226*t*
- National Oral Cancer Strategic Planning  
  Conference, 169–170
- National Oral Health Plan, 21, 284–286  
  components of, 11–13, 284–286
- National Preventive Dentistry Demonstration  
  Program, 167
- Necrotizing ulcerative gingivitis, acute, lesions  
  caused by, 99*t*
- Necrotizing ulcerative periodontitis, and HIV, 101
- Nervous system, and immune system, 28
- Neural crest, 29  
  defective development of, Treacher Collins  
    syndrome and, 48
- Neural tube, 29
- Neutrophils  
  in adult periodontitis, 40–41  
    smoking and, 41  
  in early-onset periodontitis, 42
- NHANES. *See* National Health and Nutrition  
  Examination Survey
- NHIS. *See* National Health Interview Survey
- NHSC. *See* National Health Service Corps
- Nicotine, endocrine effects of, and oral and  
  pharyngeal cancers, 46–47. *See* Tobacco
- NIH. *See* National Institutes of Health
- NIDCR. *See* National Institute of Dental and  
  Craniofacial Research
- 4-nitroquinoline-N-oxide, 45
- Nitrosamines, 46
- N-nitrosornicotine, 45
- Nociceptors, 24
- Non-Hodgkin's lymphoma, 46  
  misdiagnosis of, 101  
  Sjögren's syndrome and, 51
- Nonneuronal tissues, 29
- Nose. *See also* Olfactory system  
  embryonic formation of, 29
- Notochord, 29
- Nursing homes, in oral health care system, 225
- Nutrition, 191*t*, 250*b*. *See also* Diet  
  and birth defects, 47–48, 172, 211  
  and cancer prevention, 47, 169, 251*b*  
  and dental caries, 250*b*  
  micronutrients in  
    cancer prevention properties, 47  
    fluoride as, 160  
  and oral cancer prevention, 209*t*, 210, 251*b*  
  oral tissue as reflection of, 100–101  
  and periodontal disease, 250*b*–251*b*  
  prenatal and perinatal, 198  
  and quality of life, 135–136, 136*t*  
  and RAU, 44

## O

- Olfactory system, 24  
aging and, 32
- Oncogenes  
discovery of, 45  
and oral and pharyngeal cancer, 46
- Oral, definition of, 1, 17
- Oral bone, loss of, osteoporosis, 102–103
- Oral cavity. *See also* Mouth  
elements of, 25–28  
manifestations of systemic disease in, 37,  
97–101, 98t–100t
- Oral flora, 37  
and brain abscesses, 105
- Oral fluids, diagnostic value of, 103–104, 103t, 279,  
280t
- Oral health  
barriers to, removal of, 4, 12–13, 19, 286  
broad definition of, 2, 17–18, 133–134  
costs of, 4, 19, 227–228, 227f, 228t, 229f, 230t  
indirect, 142–144, 143t  
determinants of, 248–249  
income inequality, 249  
lifestyle, 190, 191t, 246f, 247–248, 283  
workplace effects, 249  
disparities in, 1, 4, 10, 17, 19, 88, 239, 284  
enhancement of, 267–268  
for adolescents and young adults, 257–258  
for adults, 258–262  
for children, 249–257  
insurance and, 253–255  
social and professional environment  
and, 255–257  
for elderly adults, 262–267, 263t–264t  
for elderly women, 266–267  
expenditures for, 227–228, 227f, 228t  
financing for, 228t, 229–234, 231f, 231t,  
232f  
vs. total health care expenditures, 227,  
227f, 228t  
future of, 280  
diversity of diseases and patients in, 276  
National Oral Health Plan, 284–286  
new treatments in, 276  
and general health, 2, 4–5, 10–11, 17–18, 19,  
53, 285–286  
in elderly, 265  
implications of linkages between, 122  
risk factors in, 4, 10, 18  
historical trends and, 275–276  
meaning of, 5, 17–21, 20  
of military personnel, vs. civilian population,  
83, 87, 88f  
objectives for, 267–268, 267t  
personal approaches to, 189–191  
care seeking, 190–191  
daily hygiene, 189–190  
among elderly, 262–263  
healthy lifestyle, 190, 191t  
prevention measures, 3–4, 7–9, 10, 18. *See also*  
Oral health care system  
in public health programs, 12  
ratings of, 144  
status of, 35–93  
and dental care wants, 87t  
trends in, 87–89
- Oral health care system. *See also* Dental care  
active personnel in, 223–224, 224t, 235–236,  
235f, 286  
by sex and race/ethnicity, 11, 236–237,  
237t, 286  
community approaches in  
for craniofacial birth defects, 172–173  
for dental caries, 158–168  
effectiveness of interventions by, 155–158,  
156t  
glossary of terms for, 157b  
for injury, 173–176  
for oral and pharyngeal cancers, 169–172  
for periodontal diseases, 168–169  
expanding base of, 216  
future of, 239–240  
capacity to meet needs in, 234–239  
molecular, and genomics, 278, 278f, 279  
individual approaches in  
care seeking in, 190–191  
daily hygiene in, 189–190  
among elderly, 262–263  
healthy lifestyles in, 190, 191t, 246f,  
247–249, 248f  
knowledge of and practice in, 176–179  
professional components of  
dental care, 223–224  
medical care, 225  
overlap among, 227  
public health programs, 225–227  
progress in, 179–180, 180t  
provider-based care in, 191–212. *See also*  
Provider-based care  
diagnostic tests in, 193, 193t  
future of, 212–216  
oral health assessment in, 193–196,  
194f–195f, 197t  
risk assessment in, 192–193  
public-private partnerships in, 13, 286  
strategies for, 156t  
underserved in, 239

- Oral hygiene, 189–190, 191*t*  
 and bacteremia, 104  
 and dental caries, 39, 189–190  
 among elderly, 262–263  
 and gingivitis, 39  
 and periodontal disease, 168–169, 190, 191*t*, 203*t*  
 public practices survey, 178  
 workplace effects on, 249
- Oral mucosa, 25–26  
 aging and, 32  
 lesions of, diseases and conditions causing, 98*t*–100*t*  
 nutrition and, 250*b*  
 staining of, 107
- ORN. *See* Osteoradionecrosis
- Osteogenesis imperfecta, 49
- Osteoporosis  
 and adult periodontitis, susceptibility to, 41  
 and oral bone loss, 102–103  
 and periodontal disease, 203*t*
- Osteoradionecrosis (ORN), 106
- Ottawa Charter for Health Promotion, 247
- 
- P**
- Pain  
 facial, atypical, 52  
 oral, chronic, 24  
 oral-facial, 24–25, 52  
 clinical management of, 211  
 control of, 24  
 impact of, 139–140  
 prevalence of, 73, 73*f*  
 sex differences, 25, 77  
 sleep problems with, 137
- Palate, 25  
 embryonic formation of, 29  
 lesions of, diseases and conditions causing, 98*t*–100*t*
- Papillae, as oral mucosa, 25
- Papillomavirus, oral lesions with, 71, 98*t*
- Papillon-Lefevre syndrome, and periodontal disease, 41
- Parotid glands, 26  
 aging and, 32  
 swollen, 97
- Pathogens, protection against. *See also* Immune system  
 by saliva, 27
- Pathology, systemic, craniofacial disease as model of, 53
- Pemphigus vulgaris, lesions caused by, 100*t*
- Periodontal attachment  
 loss of  
 by age, sex, race/ethnicity, and income, 65–66  
 definition of, 62*b*  
 osteoporosis and, 102
- Periodontal disease, 39–42  
 adult periodontitis. *See* Adult periodontitis  
 by age, sex, race/ethnicity, and income, 65–66  
 from bone marrow radiation, 105  
 and cardiovascular disease, 115–120  
 clinical management of, 201–209  
 diagnosis of, 203–205, 204*t*, 278  
 prevention of, 205–206, 206*t*  
 risk assessment in, 202–203, 203*t*  
 treatment of, 206–209, 206*t*
- diabetes and, 2, 17, 109–114  
 glycemic control affected by, 114–115, 116*t*–117*t*  
 research used in, 110*t*, 111*t*–113*t*
- early-onset. *See* Early-onset periodontitis
- heart disease and stroke with, 115–120  
 animal studies, 117–118  
 mechanisms of action in, 115–117  
 population-based studies, 118–120, 119*t*  
 nutrition and, 250*b*–251*b*
- pathogenesis of, 202
- preexisting, as risk factor, 202, 203*t*
- and pregnancy, adverse outcomes in, 120–122
- prevention of, 10, 168–169, 256*t*  
 daily oral hygiene and, 168–169, 190, 191*t*, 203*t*  
 dental professionals' knowledge about, 178  
 history of, 3, 18  
 provider-based, 205–206, 206*t*  
 public's knowledge about, 178  
 strategies for, 156*t*  
 risk and protective factors for, 256*t*  
 tobacco and, 259*b*, 260*b*
- Periodontal ligament  
 regeneration procedures for, 208  
 sensitivity of, 24  
 teeth in, 26  
 tissue turnover in, 31
- Periodontitis  
 adult. *See* Adult periodontitis  
 and heart disease, 118–120  
 as mixed infection, 205  
 necrotizing ulcerative, and HIV, 101  
 pathobiology of, 202, 202*f*  
 and stroke, 119–120
- Perioral skin, lesions of, diseases and conditions causing, 98*t*
- Pfeiffer's disease, 49
- PGE<sub>2</sub>. *See* Prostaglandin E<sub>2</sub>

- pH  
 in dental caries risk assessment, 197  
 saliva and, 27
- Phagocytes, in adult periodontitis, smoking and, 41
- Pharmaceuticals. *See* Medications
- Pharyngeal cancer. *See* Cancer, oral and pharyngeal
- Pharynx, 25  
 herpes simplex virus and, 109  
 lesions of, diseases and conditions causing, 98t, 100t
- Phenytoin, and gingivitis, 39, 107
- Phosphate metabolism, disturbances in, oral manifestations of, 101
- Pierre Robin syndrome, 48
- Pigmentation, of soft or hard oral tissue, as sign of disease, 100
- Pipe smoking, and cancer, 208t, 259b
- Plaque, 37, 104. *See also* Biofilm  
 control of, 39, 205–206, 206t  
 chemical, 205  
 with daily hygiene, 190  
 professional, 206  
 fluoride in, 159  
 public knowledge about, 178  
 subgingival, 40
- Pocket depths, and periodontal disease diagnosis, 204, 204t
- Point mutations, birth defects and, 31
- Polymeric resin composites, in dental caries treatment, 201
- Population, trends in, 275–276, 280
- Population groups  
 characteristics of, as determinant of health, 248, 248f  
 data on, 10, 61–62, 88  
 disabled, oral health of, 78–79  
 diversity of, future of oral care and, 277  
 oral health disparities among, 1, 4, 10, 17, 19, 88, 239, 283–284  
 oral health services targeted to, 225, 239  
 racial/ethnic minorities. *See* Race/ethnicity;  
*specific minority group*  
 women. *See* Women
- Porphyromonas gingivalis*  
 in adult periodontitis, 40, 41, 205  
 in adverse pregnancy outcomes, 121  
 and bacteremia, 104  
 in heart disease, 117  
 in periodontal disease, 203t
- Poverty, 249. *See also* Income  
 children in, oral health of, 2, 252  
 and dental care utilization, 80, 80t, 81  
 and dental caries, susceptibility to, 63–64  
 and tooth loss and edentulism, 66, 67f  
 and toothaches, 73
- PPOs. *See* Preferred provider organizations
- Precancerous lesions  
 HPV and, 45  
 and oral cancer, 44–45  
 and smokeless (spit) tobacco, 70, 70f
- Precavitated carious lesions, in restored teeth, diagnosis of, 198
- Preferred provider organizations (PPOs), 229, 232, 233t
- Pregnancy  
 adverse outcomes of, periodontal disease and, 120–122  
 and dietary fluoride supplements, 163–164  
 gingivitis in, 39
- Prenatal care, 172, 198, 210–211
- Prenatal syphilis, lesions caused by, 99t
- Prepubertal periodontitis, 42
- Prevalence, definition of, 62b
- Prevalence rate, definition of, 62b
- Prevotella intermedia*  
 in adult periodontitis, 40, 41  
 in periodontal disease, 203t  
 in prepubertal periodontitis, 42  
 smoking and, 41
- Private practice, 223–224, 227
- Probes/instrumentation, sensitivity of, 40
- Probing depths, and periodontal disease diagnosis, 204, 204t
- Prostaglandin(s)  
 and adult periodontitis, 40–41  
 and heart disease, 115  
 and pregnancy, 121
- Prostaglandin E<sub>2</sub>  
 and adult periodontitis, 40–41, 205  
 and mucositis, 106  
 and periodontal disease, and low birth weight, 121
- Proto-oncogenes  
 discovery of, 45  
 and oral cancer, 46
- Provider-based care, 191–212  
 changing approach by  
 to birth defects, 210–211  
 to dental caries, 196–201  
 to oral and pharyngeal cancers, 209–210  
 to periodontal diseases, 201–209  
 for chronic craniofacial pain and sensorimotor conditions, 211  
 diagnostic tests in, 193, 193t  
 dental caries, 198, 200t  
 oral and pharyngeal cancer, 210  
 periodontal diseases, 203–205, 204t  
 future of

Provider-based care (*continued*)  
 broadening base in, 216  
 clinical practice guidelines, 213–214, 215t  
 evidence-based practice, 213  
 science and technology contributions, 216  
 for mucosal and autoimmune diseases, 212  
 oral health assessment by, 193–196, 194f–195f, 197t  
 prevention by  
 of birth defects, 210–211  
 of dental caries, 198–200  
 of oral and pharyngeal cancer, 210  
 of periodontal diseases, 205–206, 206t  
 risk assessment by, 192–193  
 of dental caries, 197, 198t, 200t  
 of oral and pharyngeal cancer, 208t, 209–210, 209t  
 of periodontal diseases, 202–203, 203t  
 for temporomandibular disorders, 211–212  
 Pseudomembranous candidiasis, 43  
 Pterygoid muscle, 26  
 Puberty gingivitis, 39  
 Public  
 knowledge, attitudes, and practices of, 177–179, 239, 280  
 perceptions of, 11, 285  
 Public health programs. *See also* Community health programs; Medicaid; Medicare  
 for elderly, 265  
 essential services for, 181b  
 in oral health care system, 12, 225–227, 286  
 Public-private partnerships, 13, 286  
 Puerto Ricans, oral health of, 75  
 Pulmonary disease, obstructive, and oral health, 108  
 Pulp tissue  
 infections in, 24, 38  
 tissue turnover in, 31

---

**Q**


---

Quality of life  
 cultural perspectives on, 134–135  
 heightened expectations of, 146  
 oral health in, 133–134  
 functional dimensions of  
 eating problems and, 135–136, 136t  
 sleep problems and, 137  
 indirect costs of, 142–144, 143t  
 need for measurement of, 133–134  
 psychosocial dimensions of, 137–142  
 cleft lip/palate and malocclusion, 141–142  
 facial appearance, 140–141  
 oral and pharyngeal cancers, 142

oral-facial pain and, 139–140  
 social function and, 138–139, 139t  
 research on, 144–146, 146t

---

**R**


---

Race/ethnicity. *See also* specific minority group  
 and adult periodontitis, 41  
 and congenital malformations, 72, 72f  
 and dental care  
 nonutilization, 84t–85t  
 utilization, 80t, 81–82, 81t  
 wants, 87t  
 and dental caries, susceptibility to, 63–64, 63f, 64f  
 future of oral care and, 277  
 and insurance coverage, 230–231, 232f  
 and malocclusions, 72  
 in oral health workforce, 12, 236–237, 237t, 286  
 and periodontal disease, 41, 65–66, 66f  
 Radiation treatment  
 oral candidiasis and, 42  
 oral infections from, 106  
 oral ulcers and oral mucositis from, 26  
 periodontal disease from, 105  
 Radiographs, 196  
 bite-wing, 198, 200t  
 in periodontal disease diagnosis, 204, 204t  
 Rapidly progressive periodontitis, 40, 41  
 systemic antibiotics for, 207  
 Ratings, of oral health, 144  
 RAU. *See* Recurrent aphthous ulcers  
 Recurrent aphthous ulcers (RAU), 43–44  
 prevalence of, 71, 71f  
 Refractory adult periodontitis, 42  
 systemic antibiotics for, 207  
 Reimbursement, direct, 230. *See also* Dental care, financing and reimbursement  
 Relative survival rate, definition of, 62b  
 Remineralization, 27, 38, 159, 199  
 Research. *See also* Science base  
 current, 4, 5, 11, 19, 20  
 in evidence-based practice, 213, 246  
 federal studies of oral health, 268  
 need for expansion of, 285–286  
 on quality of life, 144–146, 146t  
 surveys used for health data, 61–62  
 trends in, 214–216  
 Respiratory disease, oral infections and, 108  
 Restorations  
 precavitated carious lesions in, diagnosis of, 198  
 procedures for, 201  
 Retinoids, 47



Rous sarcoma virus (RSV), and oral cancer, 45  
 RSV. *See* Rous sarcoma virus  
 Rural/urban status, and dental care wants, 87t  
 Ryan White Comprehensive AIDS Resources  
 Emergency Act, 225

## S

- S-IgA, 28  
 Saethre-Chotzen syndrome, 49  
 Saliva, 26  
   aging and, 32  
   and cariogenic bacteria, 38  
   decreased flow of  
     in dental caries risk assessment, 197  
     and chewing function, 136  
   diagnostic value of, 103–104, 103t, 279, 280t  
   fluoride and, 27, 38, 159  
   functions of  
     barrier and buffering properties, 27  
     dental caries prevention, 27  
     tissue protection, 26–27  
     wound healing, 27  
   and general health, 1, 17  
   immunoglobulins in, smoking and, 41  
 Salivary glands, 26  
   and aging, 32  
   and general health, 1, 17  
   involvement in infections, 97  
   Sjögren's syndrome and, 51  
 Satisfaction ratings, of oral health, 144  
 Scaling and root planing, for plaque removal, 206,  
 206t  
 SCHIP. *See* State Children's Health Insurance  
 Program  
 School-based programs. *See also* Dental schools;  
 Health professional schools  
   dental sealant programs in, 167  
   dietary fluoride supplements in, 164–165  
   fluoridated drinking water in, 159t, 162  
   fluoride mouthrinses in, 165  
   oral and pharyngeal cancer prevention  
   programs in, 170  
   strategies employed by, 156t  
   tobacco prevention programs in, 170  
 Science base. *See also* Research  
   and evidence-based practice, 213, 246  
   need for expansion of, 11–12, 285–286  
   in oral health, 5, 19–20  
 Scientific worldviews, 134–135  
 Scurvy, oral signs of, 101  
 Sealants. *See* Dental sealants  
 Secretory leukocyte protease inhibitor (SLPI), 27  
 Self-care. *See* Oral health care system, individual  
   approaches in  
 Senses, 23–25, 32  
 Sex  
   and adult periodontitis, susceptibility to, 41, 65,  
   65f  
   and dental care  
     nonutilization, 84t  
     utilization, 80t, 81–82, 81t  
     wants, 87t  
   of dental personnel, 236–237  
   and injuries, 73  
   and insurance coverage, 231, 232f  
   and oral and pharyngeal cancers, by race/eth-  
   nicity, 68, 68f  
   and oral clefts, 72  
   and oral health, 77–78  
     ratings of, 144  
   and pain, 25, 77  
     prevalence of, 73, 73f  
   and periodontal disease, 203t  
   and Sjögren's syndrome, prevalence of, 73  
   and taste, 78  
   and TMDs, prevalence of, 73  
   and tooth loss, 66  
 Sex hormones  
   and adult periodontitis, susceptibility to, 41  
   pain and, 25  
 Sexually transmitted diseases (STDs), oral transmis-  
 sion of, 109  
 Single-gene defects, 49–50  
 Sjögren's syndrome, 51  
   prevalence of, 73  
   swollen parotid glands with, 97  
 Skin, lesions of, diseases and conditions causing,  
 98t, 100t  
 Sleep problems, and quality of life, 137  
 SLPI. *See* Secretory leukocyte protease inhibitor  
 Smell  
   aging and, 32  
   development and function of, 23, 24  
 Smokeless (spit) tobacco. *See* Tobacco  
 Smoking. *See also* Tobacco  
   and birth defects, 48  
   cessation of, 210  
   community intervention models, 171  
   and oral cancer, 46  
   and periodontal disease, 203t, 206  
   school-based intervention models, 170  
   and trench mouth, 40  
 Social function, and dental problems, 138–139, 139t  
 Socioeconomic status. *See* Income  
 Sonic instruments, for plaque removal, 206, 206t  
 Spinal chord, early development of, 29  
 Spirochetes, and trench mouth, 40

---

## Index

- Sports injuries, 50, 73, 173–176, 174*t*–175*t*, 176*b*, 258
- Squamous cell carcinomas, oral, 44  
HPV and, 43, 45
- Stannous fluoride, to limit gingival inflammation, 205, 206*t*
- State Children's Health Insurance Program (SCHIP), 2, 13, 233–234, 255, 277
- States  
data from, need for, 10, 88, 284, 285  
on edentulism, 67*t*  
income of, and population-per-dentist ratio, 224, 224*f*  
on mortality rates for oral and pharyngeal cancer, 70, 70*t*  
public health systems in, 226–227, 286
- STDs. *See* Sexually transmitted diseases
- Steroid hormones, and gingivitis, 39
- Stevens-Johnson syndrome, lesions caused by, 100*t*
- Streptococci, 39. *See also* Mutans streptococci  
*Streptococcus sanguis*, in heart disease, 107, 117  
*Streptococcus viridans*, oral infections from, 105
- Stress  
and immune system, 28  
and periodontal disease, 203*t*, 206
- Stroke, oral infection and, 115–120  
animal studies, 117–118  
mechanisms of action in, 115–117  
population-based studies, 118–120, 119*t*
- Student indebtedness, 237–238
- Sublingual glands, 26
- Submandibular glands, 26  
aging and, 32
- Submucous fibrosis, and oral cancer, 45
- Sugars  
and dental caries, 38, 250*b*  
intake reduction of, 199  
in smokeless (spit) tobacco, 39
- Surveillance data, 61–62  
need for, 12, 88–89  
on quality of life, 144–146, 146*t*  
surveys used for, 61–62
- Survival rate, definition of, 62*b*
- Syphilis, lesions caused by, 99*t*, 109
- 
- T**
- T cells, 28  
smoking and, 41
- Tar, tobacco  
carcinogens in, 45  
dysplasia and, 46
- Tartar, and gingivitis, 39. *See also* Calculus
- Task Force on Community Preventive Services, 158, 180
- Taste  
development and function of, 23–24  
sex differences in, 78
- Tear glands, Sjögren's syndrome and, 51
- Technology, future of, 278–279
- Temperature, sensitivity to, 24–25
- Temporalis muscle, 26
- Temporomandibular disorders (TMDs), 52–53  
and chewing function, 136  
clinical management of, 211–212  
diagnosis of, 211–212, 212*t*  
pain from, impact of, 139–140  
prevalence of, 73  
and quality of life, 145–146  
treatment for, 212
- Temporomandibular joint, 26
- Teratogens, 47–48
- Tetracycline, enamel hypoplasia from, 107
- TGF- $\alpha$ . *See* Transforming growth factor  $\alpha$
- Therapeutics, oral fluids in diagnostic tests for, 103, 103*t*
- Thermoreceptors, 24
- Thrombosis, from oral cavity bacteria, 117
- Thromboxane B2, and heart disease, 115
- Thrush, 43. *See* Candidiasis  
prevalence of, 71
- Tic douloureux, 52
- TMDs. *See* Temporomandibular disorders
- TNF- $\alpha$ . *See* Tumor necrosis factor  $\alpha$
- Tobacco, 191*t*  
among adolescents, 259*b*  
and adult periodontitis, susceptibility to, 41  
and alcohol, combination of  
and oral cancer, 45, 208*t*, 209  
and dental caries, 259*b*  
as general health risk factor, 4, 10, 18  
and oral and pharyngeal cancer, 259*b*, 260*b*  
and oral cancer, 44–45, 169, 170, 208*t*, 209, 209*t*  
and oral candidiasis, 42  
oral effects of, 101  
and oral mucosal lesions, 70  
and periodontal diseases, 169, 259*b*, 260*b*  
and saliva, 27  
smokeless (spit) tobacco  
among adolescents, 257  
and dental caries, 259*b*  
and oral and pharyngeal cancer, 44–45, 208*t*, 259*b*  
and oral mucosal lesions, 70, 70*f*  
and periodontal diseases, 259*b*

- prevention programs for, 170
    - and tooth decay, 39
  - trends in use of, 259b–260b
  - Tongue
    - cancer in, 70
    - lesions of, diseases and conditions causing, 98t–100t
  - Tooth/teeth, 26
    - aging of, 31
    - birth defects involving, 48–49, 50
    - clenching of, 190, 191t, 212
    - conically shaped, in ectodermal dysplasias, 50
    - cultural significance of, 137–138
    - decay in. *See* Dental caries
    - embryonic development of, 30
    - grinding of, 52, 212
    - loss of
      - by age, socioeconomic status, sex, and race/ethnicity, 66–67
      - and chewing function, 135–136
    - malocclusions. *See* Malocclusions
    - nutrition in development of, 250b
    - pain in, 24
    - primary, 26
    - restored. *See* Restorations
    - staining of, 107
    - thermal sensitivity in, 24
    - trauma to
      - from falls, 50
      - prevalence of, 72
  - Toothbrushing, 39, 176, 179, 190
    - and bacteremia, 104
    - public knowledge of
      - for dental caries prevention, 177
      - for gum disease prevention, 178
    - public practices, 178
  - Toothaches, prevalence of, 73, 73f
  - Toothpaste. *See* Dentifrice
  - Touch, sense of, in mouth, 24
  - Toxic-shock-like syndrome (TSLs), 105
  - Toxins, saliva and, 27, 103, 103t
  - Transforming growth factor  $\alpha$  (TGF- $\alpha$ ), and oral and pharyngeal cancers, 46, 47
  - Trauma. *See also* Injury, and oral-facial
    - prevention of, strategies for, 156t
    - and RAU, 44
  - Traumatic ulcers, lesions caused by, 100t
  - Treacher Collins syndrome, 48
  - Treatment(s). *See also specific disease*
    - future of, 276
    - outcomes
      - as determinant of health, 248, 248f
      - measurement of, 133
  - Trench mouth, 40
    - lesions with, 99t
  - Treponema*, and gingivitis, 39
  - Treponema denticola*, in adult periodontitis, 40, 205
  - Triclosan copolymer, to limit gingival inflammation, 205, 206t
  - Trigeminal ganglion, oral herpes and, 43
  - Trigeminal neuralgia, 52
  - TSLs. *See* Toxic-shock-like syndrome
  - Tuberculosis, lesions caused by, 99t
  - Tumor necrosis factor  $\alpha$  (TNF- $\alpha$ )
    - and adult periodontitis, 41, 205
    - and glycemic control, 114
    - and heart disease, 115
    - and pregnancy, 121
  - Tumor suppressor genes, mutations of, in oral and pharyngeal cancer, 46
- 
- U**
- Ulcerative colitis, and RAU, 44
  - Ultrasonic instruments, for plaque removal, 206, 206t
  - U.S. Department of Agriculture, 225
  - U.S. Department of Defense, 225
  - U.S. Department of Health and Human Services (USDHHS), 225, 226, 226t
  - U.S. Department of Justice, 225
  - U.S. Department of Transportation, 225
  - U.S. Department of Veterans Affairs, 225
  - U.S. Preventive Services Task Force, 156–158
  - USDHHS. *See* U.S. Department of Health and Human Services
- 
- V**
- Van der Woude syndrome, 48
  - Varicella-zoster virus
    - and chemotherapy, 106
    - oral lesions with, 98t
  - Vascular endothelial growth factor (VEGF), 27
  - VEGF. *See* Vascular endothelial growth factor
  - Veillonella parvula*, and gingivitis, 39
  - Velocardiofacial syndrome, 48
  - Venereal warts, 71
  - VGS. *See* Viridans group streptococci
  - Vietnamese Americans, nasopharyngeal cancer incidence and mortality, 76
  - Vincent's infection, 40
    - lesions caused by, 99t
  - Violence, 51, 72–73
  - Viridans group streptococci (VGS), 105
  - Viridans streptococcal shock syndrome (VSSS), 105

- Viruses. *See also specific virus*  
chemotherapy and, 106  
lesions caused by, 98*t*  
oral cancer and, 45–46
- Vitamin B deficiency, oral signs of, 101
- Vitamin C deficiency  
and cancer, 251*b*  
oral signs of, 101
- Vitamin D deficiency, oral signs of, 101
- Vitamin E, 47  
cancer and, 251*b*  
and mucositis, 106
- VSSS. *See* Viridans streptococcal shock syndrome
- 
- W**
- 
- Waardenburg syndrome, 50
- Warts, viral, 43  
oral lesions with, 98*t*
- Water fluoridation. *See* Fluoride, in drinking water
- Well-being  
and oral diseases, 10, 11  
and oral health, 2, 4–5, 18, 19  
in World Health Organization (WHO)  
definition of health, 133
- Western scientific worldviews, 134–135
- WHO. *See* World Health Organization
- WIC. *See* Women, Infants, and Children program
- Wolinella recta*, in adult periodontitis, 41
- Women  
and adult periodontitis, susceptibility to, 41, 65, 65*f*  
and dental care nonutilization, 84*t*  
as dental personnel, 236  
in dentistry, 223–224, 224*t*  
elderly, risk factors for, 266–267  
and injuries, 73  
and oral and pharyngeal cancers, 68, 68*f*  
and oral bone loss, 102–103  
oral health of, 77–78, 266–267  
areas of study in, 78, 78*f*  
and pain, 25, 77–78  
prevalence of, 73, 73*f*  
TMDs, 52, 73  
and Sjögren's syndrome, prevalence of, 73
- Women, Infants, and Children (WIC) program, 225, 256
- Workplace effects, on oral health, 249
- World Health Organization (WHO) 18, 133
- 
- X**
- 
- Xenografts, 208
- Xerostomia. *See* Dry mouth  
and dental caries, 38  
and oral candidiasis, 42
- Xerostomic side effects, of medication, 107
- 
- Y**
- 
- Yeast. *See* *Candida albicans*